{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-001787","form_type":"8-K","ticker":"RNXT","cik":"0001574094","company_name":"RenovoRx, Inc.","filed_at":"2023-01-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.659606+00:00","generated_at":"2026-06-20T14:02:05.809872+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"RenovoRx PK substudy shows >50% reduction in systemic drug exposure with RenovoTAMP","bullets":["In 13 LAPC patients, intra-arterial gemcitabine via RenovoTAMP reduced systemic drug exposure by >50% vs IV.","Data presented at ASCO GI Symposium January 19-21, 2023, along with three additional abstracts.","TIGeR-PaC trial: 47 of 114 target patients randomized; 25 deaths reported to date.","Additional abstracts cover mesenteric venous thrombosis prevalence and SBRT vs IMRT tolerability."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-001787","json":"https://secwatch.observer/filing/0001493152-23-001787.json","markdown":"https://secwatch.observer/filing/0001493152-23-001787.md","text":"https://secwatch.observer/filing/0001493152-23-001787.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1574094/000149315223001787/0001493152-23-001787-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1574094/000149315223001787/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T14:02:05.809872+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}